+247.3%
PM vs MRNA
+878.5%
-631.2%
-31.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.5% | -3.6% | +2.2% | -1.5% |
| 7D | +1.5% | -20.0% | +21.5% | +1.6% |
| 30D | -4.5% | -1.3% | -3.2% | -4.5% |
| 3M | +3.9% | +240.0% | -236.1% | +2.8% |
| 6M | +5.1% | +339.0% | -333.8% | +4.0% |
| YTD | +25.4% | +630.0% | -604.6% | +23.6% |
| 1Y | +30.6% | +769.1% | -738.5% | +28.6% |
| 3Y | +142.9% | +181.2% | -38.3% | +141.5% |
| 5Y | +165.1% | -8.1% | +173.2% | +164.4% |
| All | +247.3% | +878.5% | -631.2% | +225.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling